No Data
No Data
Olema Pharmaceuticals Announces Preclinical Data Supporting OP-3136's Potential in Ovarian, Prostate, and Lung Cancers, Phase 1 Trial Ongoing
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $27
Promising Outlook for Olema Pharmaceuticals: Buy Rating Affirmed Amid Strategic Positioning in ER+ Breast Cancer Treatment
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)